Table 1 Baseline characteristics.
From: Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
Janssen Ad26COV-2 | Moderna mRNA-1273 | Pfizer BNT162b2 | |
|---|---|---|---|
No. of participants | 20 | 16 | 31 |
Sex – no. (%) | |||
Female | 9 (45) | 6 (37) | 16 (52) |
Male | 11 (55) | 10 (63) | 15 (48) |
Age, years | |||
18–55 years old – no. (%) | 11 (55) | 9 (56) | 25 (81) |
56+ years old – no. (%) | 9 (45) | 7 (44) | 6 (19) |
Mean ± SD | 50.3 ± 15.9 | 48.4 ± 14.7 | 43.2 ± 11.9 |
Range | 25–77 | 19–66 | 19–62 |
Race and ethnic group – no. (%)a | |||
American or Alaska Native | 0 (0) | 0 (0) | 0 (0) |
Asian | 0 (0) | 0 (0) | 4 (13) |
Black or African American | 3 (15) | 5 (31) | 10 (32) |
Multiracial | 3 (15) | 1 (6) | 1 (3) |
Native Hawaiian or other Pacific Islander | 0 (0) | 0 (0) | 0 (0) |
White | 14 (70) | 10 (63) | 15 (49) |
Other race | 0 (0) | 0 (0) | 1 (3) |
Hispanic or Latino ethnicity | 2 (10) | 2 (13) | 3 (10) |
Ethnic group not reported or unknown | 1 (5) | 0 (0) | 0 (3) |
Vaccine doses prior to Novavax boostb | |||
One dose | 4 | NA | NA |
Two doses | 16 | 16 | 31 |
The interval from last prior vaccine dose, weeksc | |||
Mean ± SD | 32.8 ± 8.9 | 42.2 ± 13.3 | 42.9 ± 13.1 |
Range | 12.7–54.1 | 14.3–59.0 | 18.7–76.1 |
Interval between first and second prior vaccine doses, weeksd | |||
Mean ± SD | 22.5 ± 8.2 | 4.8 ± 1.3 | 3.2 ± 0.5 |
Range | 15–43 | 4–8.7 | 2.7–5.3 |
Serology anti N-protein Ab test at baseline | |||
Negative | 17 (85) | 11 (69) | 20 (65) |
Positive | 3 (15) | 5 (31) | 11 (35) |
